The Evolution of In-Field Medical Affairs: Introducing the Strategic Scientific Advisor

被引:0
作者
Anechina, Lucia Regadera [1 ]
Iglesias, Inmaculada [1 ]
Marinich, Jorge A. [1 ]
Diago, Jesus [1 ]
Dominguez, Ana Perez [1 ]
机构
[1] AstraZeneca Farmaceut Spain, Med Affairs Dept, C Puerto Somport 21-23,Fuencarral El Pardo, Madrid 28050, Spain
关键词
D O I
10.1007/s40290-025-00551-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The evolving landscape of healthcare demands a transformation in Medical Affairs (MA) to address new challenges and opportunities. This article presents the Strategic Scientific Advisor (SSA) role as a critical innovation within our MA department, aimed at enhancing early engagement with stakeholders and strategically positioning assets within the healthcare ecosystem. The SSA role was developed following a comprehensive external assessment and an internal review of the MA department's structure to integrate the CARABELA methodology, which serves as the foundation for SSA activities. CARABELA is a joint initiative between AstraZeneca and key scientific societies to optimize clinical practices in specific chronic diseases using a holistic strategy, whose implementation is monitored in each hospital by applying specifically designed indicators. The SSA role design, guided by the Strategic Scientific Area Plan Framework, emphasizes early proactive engagement, evidence generation, and a multidisciplinary approach to optimizing clinical practices. By fostering collaboration across internal teams and external partners, the SSA supports activities throughout the entire lifecycle of the product, facilitating early access strategies, and building tailored plans to address unmet medical needs. In contrast to traditional Medical Science Liaisons (MSLs), SSAs play pivotal roles in driving long-term healthcare outcomes, aligning with the Medical Affairs 2030 vision. The SSA is trained and evaluated to catalyze a strategic shift, enabling MA to address the complexities of healthcare ecosystems, improve clinical practices, and contribute to patient-centered innovations. This transformation underscores the critical need for MA professionals to expand beyond traditional responsibilities and lead initiatives that shape the future of healthcare.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 21 条
  • [1] Evers M., Ghatak A., Holt E., Ostojic I., Pradel C., Suresh B., Et al., A Vision for Medical Affairs in 2025
  • [2] Fulford-Smith A., Leah E., Azroyan A., De Abadal M., Loew D., Hildemann S., Medical affairs transformation in specialty pharma: next-level collaboration at the core, Pharmaceut Med, 36, 2, pp. 63-69, (2022)
  • [3] The future of medical affairs 2030, Medical Affairs Professional Society [Internet]
  • [4] 2022
  • [5] Algazy J., Garcia A., Ryan S., Westra A., Zemp A., A Vision for Medical Affairs 2030: Five Priorities for Patient Impact, (2023)
  • [6] Plantevin L., Schlegel C., Gordian M., Reinventing the Role of Medical Affairs. a Strategic Overhaul of Medical Affairs Can Help Pharma Companies Win in an Era of Big Data Medicine, (2017)
  • [7] Furtner D., Hutas G., Tan B.J.W., Meier R., Journey from an Enabler to a strategic leader: integration of the medical affairs function in ESG initiatives and values, Pharmaceut Med, 37, 6, pp. 405-416, (2023)
  • [8] Gores M., Berkels R., Medical affairs’ next frontier: unlocking omnichannel engagement. How to build deeper customer relationships through personalized experiences. IQVIA
  • [9] 2022, (2024)
  • [10] Bradford K., Logue A., Erdemli B., Beyond the field: Evolving field medical engagement and talent for the future, A MAPS White Paper, (2021)